Pfizer Statistics
Total Valuation
Pfizer has a market cap or net worth of $153.81 billion. The enterprise value is $207.86 billion.
Important Dates
The last earnings date was Tuesday, February 3, 2026, before market open.
| Earnings Date | Feb 3, 2026 |
| Ex-Dividend Date | Jan 23, 2026 |
Share Statistics
Pfizer has 5.69 billion shares outstanding. The number of shares has increased by 0.23% in one year.
| Current Share Class | 5.69B |
| Shares Outstanding | 5.69B |
| Shares Change (YoY) | +0.23% |
| Shares Change (QoQ) | -0.49% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 66.55% |
| Float | 5.68B |
Valuation Ratios
The trailing PE ratio is 19.89 and the forward PE ratio is 9.13.
| PE Ratio | 19.89 |
| Forward PE | 9.13 |
| PS Ratio | 2.46 |
| Forward PS | 2.52 |
| PB Ratio | 1.78 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 16.95 |
| P/OCF Ratio | 13.14 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 8.08, with an EV/FCF ratio of 22.91.
| EV / Earnings | 26.75 |
| EV / Sales | 3.32 |
| EV / EBITDA | 8.08 |
| EV / EBIT | 10.85 |
| EV / FCF | 22.91 |
Financial Position
The company has a current ratio of 1.16, with a Debt / Equity ratio of 0.78.
| Current Ratio | 1.16 |
| Quick Ratio | 0.80 |
| Debt / Equity | 0.78 |
| Debt / EBITDA | 2.54 |
| Debt / FCF | 7.45 |
| Interest Coverage | 7.17 |
Financial Efficiency
Return on equity (ROE) is 8.89% and return on invested capital (ROIC) is 13.65%.
| Return on Equity (ROE) | 8.89% |
| Return on Assets (ROA) | 5.68% |
| Return on Invested Capital (ROIC) | 13.65% |
| Return on Capital Employed (ROCE) | 11.20% |
| Weighted Average Cost of Capital (WACC) | 5.48% |
| Revenue Per Employee | $834,387 |
| Profits Per Employee | $103,613 |
| Employee Count | 75,000 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 1.41 |
Taxes
| Income Tax | -266.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +4.28% in the last 52 weeks. The beta is 0.41, so Pfizer's price volatility has been lower than the market average.
| Beta (5Y) | 0.41 |
| 52-Week Price Change | +4.28% |
| 50-Day Moving Average | 26.24 |
| 200-Day Moving Average | 25.11 |
| Relative Strength Index (RSI) | 53.27 |
| Average Volume (20 Days) | 39,464,330 |
Short Selling Information
The latest short interest is 146.38 million, so 2.57% of the outstanding shares have been sold short.
| Short Interest | 146.38M |
| Short Previous Month | 129.80M |
| Short % of Shares Out | 2.57% |
| Short % of Float | 2.58% |
| Short Ratio (days to cover) | 2.69 |
Income Statement
In the last 12 months, Pfizer had revenue of $62.58 billion and earned $7.77 billion in profits. Earnings per share was $1.36.
| Revenue | 62.58B |
| Gross Profit | 47.44B |
| Operating Income | 19.16B |
| Pretax Income | 7.52B |
| Net Income | 7.77B |
| EBITDA | 25.72B |
| EBIT | 19.16B |
| Earnings Per Share (EPS) | $1.36 |
Full Income StatementBalance Sheet
The company has $13.60 billion in cash and $67.65 billion in debt, with a net cash position of -$54.05 billion or -$9.51 per share.
| Cash & Cash Equivalents | 13.60B |
| Total Debt | 67.65B |
| Net Cash | -54.05B |
| Net Cash Per Share | -$9.51 |
| Equity (Book Value) | 86.78B |
| Book Value Per Share | 15.21 |
| Working Capital | 5.91B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $11.70 billion and capital expenditures -$2.63 billion, giving a free cash flow of $9.08 billion.
| Operating Cash Flow | 11.70B |
| Capital Expenditures | -2.63B |
| Free Cash Flow | 9.08B |
| FCF Per Share | $1.60 |
Full Cash Flow StatementMargins
Gross margin is 75.81%, with operating and profit margins of 30.62% and 12.42%.
| Gross Margin | 75.81% |
| Operating Margin | 30.62% |
| Pretax Margin | 12.02% |
| Profit Margin | 12.42% |
| EBITDA Margin | 41.10% |
| EBIT Margin | 30.62% |
| FCF Margin | 14.50% |
Dividends & Yields
This stock pays an annual dividend of $1.72, which amounts to a dividend yield of 6.36%.
| Dividend Per Share | $1.72 |
| Dividend Yield | 6.36% |
| Dividend Growth (YoY) | 1.78% |
| Years of Dividend Growth | 15 |
| Payout Ratio | 126.07% |
| Buyback Yield | -0.23% |
| Shareholder Yield | 6.13% |
| Earnings Yield | 5.05% |
| FCF Yield | 5.90% |
Dividend DetailsAnalyst Forecast
The average price target for Pfizer is $27.83, which is 2.88% higher than the current price. The consensus rating is "Hold".
| Price Target | $27.83 |
| Price Target Difference | 2.88% |
| Analyst Consensus | Hold |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | -3.33% |
| EPS Growth Forecast (5Y) | 10.23% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on July 1, 1999. It was a forward split with a ratio of 3:1.
| Last Split Date | Jul 1, 1999 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
Pfizer has an Altman Z-Score of 2.11 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.11 |
| Piotroski F-Score | 6 |
